Ionis Pharmaceuticals, Inc. (BMV:IONS)
Mexico
· Delayed Price · Currency is MXN 1,150.00
+50.00 (4.55%)
At close: Sep 24, 2025
Ionis Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 372.26 | 242.08 | 399.27 | 276.47 | 869.19 | Upgrade
|
| Short-Term Investments | 2,308 | 2,061 | 1,938 | 1,721 | 1,264 | Upgrade
|
| Cash & Short-Term Investments | 2,680 | 2,303 | 2,338 | 1,997 | 2,133 | Upgrade
|
| Cash Growth | 16.39% | -1.48% | 17.03% | -6.37% | 12.32% | Upgrade
|
| Receivables | 66.06 | 92.19 | 97.78 | 25.54 | 61.9 | Upgrade
|
| Inventory | 10.05 | 12.51 | 7.44 | 22.03 | 24.81 | Upgrade
|
| Other Current Assets | 234.08 | 212.67 | 199.13 | 157.72 | 125.17 | Upgrade
|
| Total Current Assets | 2,991 | 2,620 | 2,642 | 2,203 | 2,345 | Upgrade
|
| Property, Plant & Equipment | 361.6 | 256.11 | 242.94 | 255.84 | 196.04 | Upgrade
|
| Long-Term Investments | 52.21 | 41.02 | 42.99 | 40.37 | 32.32 | Upgrade
|
| Other Long-Term Assets | 119.4 | 86.26 | 62.29 | 34.97 | 38.28 | Upgrade
|
| Total Assets | 3,524 | 3,004 | 2,990 | 2,534 | 2,612 | Upgrade
|
| Accounts Payable | 28.08 | 42.96 | 26.03 | 17.92 | 11.9 | Upgrade
|
| Accrued Expenses | 222.33 | 178.05 | 215.62 | 189.28 | 127.37 | Upgrade
|
| Current Portion of Long-Term Debt | 445.63 | 0.22 | 45.07 | 0.32 | 0.9 | Upgrade
|
| Current Portion of Leases | 9.06 | 9.06 | 8.09 | 7.22 | 2.63 | Upgrade
|
| Current Income Taxes Payable | 2.71 | 0.03 | 2.15 | 6.25 | 0.04 | Upgrade
|
| Current Unearned Revenue | 73.76 | 78.99 | 151.13 | 90.58 | 97.71 | Upgrade
|
| Total Current Liabilities | 781.57 | 309.32 | 448.09 | 311.56 | 240.55 | Upgrade
|
| Long-Term Debt | 1,899 | 1,788 | 1,743 | 1,183 | 1,228 | Upgrade
|
| Long-Term Leases | 262.38 | 161.81 | 170.88 | 178.94 | 19.43 | Upgrade
|
| Long-Term Unearned Revenue | 92 | 156.5 | 241.18 | 287.77 | 351.88 | Upgrade
|
| Total Liabilities | 3,035 | 2,415 | 2,603 | 1,961 | 1,840 | Upgrade
|
| Common Stock | 0.16 | 0.16 | 0.14 | 0.14 | 0.14 | Upgrade
|
| Additional Paid-In Capital | 3,145 | 2,869 | 2,215 | 2,060 | 1,964 | Upgrade
|
| Retained Earnings | -2,631 | -2,250 | -1,796 | -1,430 | -1,160 | Upgrade
|
| Comprehensive Income & Other | -25.28 | -30.81 | -32.65 | -57.48 | -32.67 | Upgrade
|
| Total Common Equity | 489.09 | 588.35 | 386.69 | 572.89 | 771.74 | Upgrade
|
| Shareholders' Equity | 489.09 | 588.35 | 386.69 | 572.89 | 771.74 | Upgrade
|
| Total Liabilities & Equity | 3,524 | 3,004 | 2,990 | 2,534 | 2,612 | Upgrade
|
| Total Debt | 2,616 | 1,959 | 1,967 | 1,369 | 1,251 | Upgrade
|
| Net Cash (Debt) | 64.58 | 344.14 | 370.23 | 628.21 | 882.13 | Upgrade
|
| Net Cash Growth | -81.23% | -7.05% | -41.07% | -28.78% | -8.06% | Upgrade
|
| Net Cash Per Share | 0.40 | 2.30 | 2.59 | 4.43 | 6.26 | Upgrade
|
| Filing Date Shares Outstanding | 165.19 | 158.96 | 145.75 | 142.95 | 141.69 | Upgrade
|
| Total Common Shares Outstanding | 163.3 | 157.91 | 144.34 | 142.06 | 141.21 | Upgrade
|
| Working Capital | 2,209 | 2,311 | 2,194 | 1,891 | 2,104 | Upgrade
|
| Book Value Per Share | 2.99 | 3.73 | 2.68 | 4.03 | 5.47 | Upgrade
|
| Tangible Book Value | 489.09 | 588.35 | 386.69 | 572.89 | 771.74 | Upgrade
|
| Tangible Book Value Per Share | 2.99 | 3.73 | 2.68 | 4.03 | 5.47 | Upgrade
|
| Land | - | 8.57 | 8.57 | 8.57 | 23.06 | Upgrade
|
| Buildings | 41.8 | 41.23 | 41.23 | 41.16 | 144.05 | Upgrade
|
| Machinery | 11.72 | 9.86 | 9.84 | 9.58 | 10.59 | Upgrade
|
| Leasehold Improvements | 89.15 | 54.38 | 28.28 | 28.36 | 20.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.